Drug ID | DDPD00199 |
|
Drug Name | Erythromycin | |
Molecular Weight | 733.9268 | |
Molecular Formula | C37H67NO13 | |
CAS Number | 114-07-8 | |
SMILES | CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O | |
External Links | ||
DRUGBANK | DB00199 | |
T3DB | T3D4764 | |
PubChem Compound | 12560 | |
PDR | 1071 | |
Drugs.com | Drugs.com Drug Page |
Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
---|---|---|---|---|---|
Log P | 2.6 | - | 2.6 | - | http://www.t3db.ca/toxins/T3D4764 |
Boiling Point | 719.69 | ℃ | 719.69 | ℃ | https://www.chemicalbook.com/ChemicalProductProperty_US_CB8300078.aspx |
Melting Point | 189.5 | ℃ | 133-135 | ℃ | https://www.chemicalbook.com/ChemicalProductProperty_US_CB8300078.aspx |
Water Solubility | 2000.0 | mg/L | 2 | mg/ml | https://www.chemicalbook.com/ChemicalProductProperty_US_CB8300078.aspx |
pKa | 8.88 | - | 8.88 | - | https://www.chemicalbook.com/ChemicalProductProperty_US_CB8300078.aspx |
Log S | -3.2 | - | -3.2 | - | http://www.t3db.ca/toxins/T3D4764 |
Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
---|---|---|---|---|---|---|---|
AUC | 7300.0 | ng.h/ml | 7.3±3.9 | mg.h/l | PO, oral; | DRUGBANK | |
Bioavailability | 31.5 | % | 18-45 | % | PO, oral; | DRUGBANK | |
Bioavailability | 35.0 | % | 35±25 | % | The Pharmacological Basis of Therapeutics | ||
C Max | 1.8 | ng/ml | 1.8 | mcg/L | PO, oral; | DRUGBANK | |
C Max | 2200.0 | ng/ml | 0.9-3.5 | mcg/ml | PO, oral; extended release formulation; | The Pharmacological Basis of Therapeutics | |
C Max | 950.0 | ng/ml | 0.5-1.4 | mcg/ml | Tablet, PO, oral; | The Pharmacological Basis of Therapeutics | |
T Max | 1.2 | h | 1.2 | h | PO, oral; | DRUGBANK | |
T Max | 3.0 | h | 2.1-3.9 | h | PO, oral; extended release formulation; | The Pharmacological Basis of Therapeutics | |
T Max | 2.5 | h | 2-3 | h | Tablet, PO, oral; | The Pharmacological Basis of Therapeutics | |
Clearance | 0.53 | L/h/kg | 0.53±0.13 | l/h/kg | intravenous injection, IV; normal,healthy; | DRUGBANK | |
Clearance | 42.2 | L/h | 42.2±10.1 | L/h | Hepatitis, Hep; patients; | Hepatitis, Hep ↓ ; | DRUGBANK |
Clearance | 113.2 | L/h | 113.2±44.2 | L/h | normal,healthy; patients; | DRUGBANK | |
Clearance | 0.55 | L/h/kg | 9.1±4.1 | ml/min/kg | hydrolysis; | RD, renal impairment, Renal disease,including uremia → ; | The Pharmacological Basis of Therapeutics |
Clearance | 0.34 | L/h/kg | 5.6 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset | |
Volume of Distribution | 0.78 | L/kg | 0.78±0.44 | L/kg | RD, renal impairment, Renal disease,including uremia ↑ ; | The Pharmacological Basis of Therapeutics | |
Volume of Distribution | 0.95 | L/kg | 0.95 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset | |
Half-life | 3.5 | h | 3.5 | h | elimination half-life; PO, oral; different study; | DRUGBANK | |
Half-life | 2.8 | h | 2.4-3.1 | h | elimination half-life; PO, oral; different study; | DRUGBANK | |
Half-life | 1.6 | h | 1.6±0.7 | h | Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease,including uremia → ; | The Pharmacological Basis of Therapeutics | |
Half-life | 2.0 | h | 2 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset | |
Toxicity LD50 | 9272.0 | mg/kg | 9272.0 | mg/kg | PO, oral; Rattus, Rat; | DRUGBANK | |
Eliminate Route | 5.0 | % | <5 | % | Urinary excretion; PO, oral; | DRUGBANK | |
Eliminate Route | 12.0 | % | 12±7 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics | |
Protein Binding | 85.0 | % | 80-90 | % | DRUGBANK | ||
Protein Binding | 84.0 | % | 84±3 | % | RD, renal impairment, Renal disease,including uremia → ; | The Pharmacological Basis of Therapeutics |
Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
---|---|---|---|---|---|---|---|---|
Max dose for neonates | 50.0 | mg/kg/day | 50 | mg/kg/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for neonates | 40.0 | mg/kg/day | 40 | mg/kg/day | intravenous injection, IV | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for infants | 50.0 | mg/kg/day | 50 | mg/kg/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for infants | 100.0 | mg/kg/day | 100 | mg/kg/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for infants | 20.0 | mg/kg/day | 20 | mg/kg/day | intravenous injection, IV | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for infants | 40.0 | mg/kg/day | 40 | mg/kg/day | intravenous injection, IV | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for children | 50.0 | mg/kg/day | 50 | mg/kg/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for children | 100.0 | mg/kg/day | 100 | mg/kg/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for children | 20.0 | mg/kg/day | 20 | mg/kg/day | intravenous injection, IV | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for children | 40.0 | mg/kg/day | 40 | mg/kg/day | intravenous injection, IV | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for children | 2000.0 | mg/day | 2 | g/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for children | 4000.0 | mg/day | 4 | g/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for children | 4000.0 | mg/day | 4 | g/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for children | 4000.0 | mg/day | 4 | g/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for adolescents | 50.0 | mg/kg/day | 50 | mg/kg/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for adolescents | 100.0 | mg/kg/day | 100 | mg/kg/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for adolescents | 20.0 | mg/kg/day | 20 | mg/kg/day | intravenous injection, IV | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for adolescents | 40.0 | mg/kg/day | 40 | mg/kg/day | intravenous injection, IV | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for adolescents | 2000.0 | mg/day | 2 | g/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for adolescents | 4000.0 | mg/day | 4 | g/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for adolescents | 4000.0 | mg/day | 4 | g/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for adolescents | 4000.0 | mg/day | 4 | g/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for adults | 4000.0 | mg/day | 4 | g/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for adults | 4000.0 | mg/day | 4 | g/day | intravenous injection, IV | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for geriatric | 4000.0 | mg/day | 4 | g/day | PO, oral | Erythrocin Stearate | erythromycin stearate | PDR |
Max dose for geriatric | 4000.0 | mg/day | 4 | g/day | intravenous injection, IV | Erythrocin Stearate | erythromycin stearate | PDR |